Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States.
Slightly overvalued with limited growth.
Share Price & News
How has Paratek Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PRTK's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PRTK underperformed the US Pharmaceuticals industry which returned 6.5% over the past year.
Return vs Market: PRTK underperformed the US Market which returned 19.4% over the past year.
Price Volatility Vs. Market
How volatile is Paratek Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StDid You Manage To Avoid Paratek Pharmaceuticals's (NASDAQ:PRTK) Devastating 85% Share Price Drop?
1 month ago | Simply Wall StWhen Will Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Breakeven?
3 months ago | Simply Wall StEarnings Update: Paratek Pharmaceuticals, Inc. Just Reported And Analysts Are Trimming Their Forecasts
Is Paratek Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PRTK ($3.5) is trading below our estimate of fair value ($122.02)
Significantly Below Fair Value: PRTK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PRTK is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: PRTK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PRTK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PRTK has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.
How is Paratek Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PRTK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PRTK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PRTK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PRTK's revenue (42.3% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: PRTK's revenue (42.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PRTK's Return on Equity is forecast to be high in 3 years time
How has Paratek Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PRTK is currently unprofitable.
Growing Profit Margin: PRTK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PRTK is unprofitable, and losses have increased over the past 5 years at a rate of -21.8% per year.
Accelerating Growth: Unable to compare PRTK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRTK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).
Return on Equity
High ROE: PRTK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Return on Assets
Return on Capital Employed
How is Paratek Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PRTK has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: PRTK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Inventory Level: PRTK has a low level of unsold assets or inventory.
Debt Coverage by Assets: PRTK has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PRTK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PRTK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Paratek Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate PRTK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PRTK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PRTK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PRTK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PRTK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Evan Loh (60yo)
Dr. Evan Loh, M.D., FACC, FAHA, has been the Chief Executive Officer of Paratek Pharmaceuticals, Inc. since June 25, 2019. Dr. Loh was the President at Paratek Pharmaceuticals, Inc. since June 2014 until J ...
CEO Compensation Analysis
Compensation vs Market: Evan's total compensation ($USD2.63M) is above average for companies of similar size in the US market ($USD519.76K).
Compensation vs Earnings: Evan's compensation has been consistent with company performance over the past year.
|Executive Chairman||5.7yrs||US$2.83m||1.26% $1.5m|
|CEO & Director||0.7yrs||US$2.63m||0.86% $999.6k|
|VP, Controller and Interim Principal Financial & Accounting Officer||0.8yrs||no data||no data|
|Senior Vice President of Regulatory||3.1yrs||no data||0.15% $179.7k|
|Executive Director of Investor Relations & Corporate Communications||0yrs||no data||no data|
|Senior VP||4.7yrs||US$1.87m||0.33% $383.9k|
|Vice President of Medical Strategy & Communications||2.1yrs||no data||no data|
|Vice President of Marketing||2.1yrs||no data||no data|
|Senior Vice President of Human Resources||4.4yrs||no data||no data|
Experienced Management: PRTK's management team is considered experienced (2.1 years average tenure).
|Executive Chairman||5.7yrs||US$2.83m||1.26% $1.5m|
|CEO & Director||0.7yrs||US$2.63m||0.86% $999.6k|
|Independent Director||5.3yrs||US$217.14k||0.053% $61.7k|
|Outside Director||5.3yrs||US$240.39k||0.015% $17.5k|
|Outside Director||3.9yrs||US$206.64k||0.063% $73.5k|
|Outside Director||4.6yrs||US$204.89k||0.063% $73.5k|
|Outside Director||5.3yrs||US$210.39k||0.043% $49.9k|
Experienced Board: PRTK's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PRTK insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.3%.
Paratek Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Paratek Pharmaceuticals, Inc.
- Ticker: PRTK
- Exchange: NasdaqGM
- Founded: 1996
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$116.508m
- Shares outstanding: 33.29m
- Website: https://paratekpharma.com
Number of Employees
- Paratek Pharmaceuticals, Inc.
- 75 Park Plaza
- 4th Floor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PRTK||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Oct 2014|
|N4CN||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2014|
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/19 01:27|
|End of Day Share Price||2020/02/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.